Dosage Forms

Articles

EMA has approved the manufacturing of drug product for BioNTech’s COVID-19 vaccine, BNT162b2, at BioNTech’s manufacturing site located in Marburg, Germany. 

EMA Approves BioNTech’s COVID-19 Vaccine Manufacturing Site

AstraZeneca has released the results of its primary analysis of the Phase III trial data evaluating its COVID-19 vaccine.

AstraZeneca Confirms Vaccine Efficacy with Phase III Primary Analysis

After releasing US Phase III trial data for AZD1222, more questions have been raised with AstraZeneca concerning potentially outdated information that could provide an incomplete view of efficacy.

AstraZeneca COVID-19 Vaccine Woes Continue as Questions are Raised over US Trial Data 

Rena Verma is a Senior Managing Director in FTI Technology’s Information Governance, Privacy and Security Practice. Rena has been providing advisory solutions to Fortune 500 legal departments and law firms in information governance, electronic discovery, legal technology and legal operations for nearly two decades. Rena's clients include some of the largest pharmaceuticals companies, banks, insurance, transportation and technology companies.

To maintain business continuity and employee safety during the pandemic, many companies have begun tracking and maintaining records of employee health information.

Privacy and COVID-19 Clash, Creating Unprecedented Risks for Pharma

Under an expanded agreement with J&J, Catalent Biologics will increase manufacturing capacity at its Anagni, Italy, site to accommodate the large-scale commercial supply of Janssen’s COVID-19 vaccine. 

Catalent to Increase Manufacturing Capacity at Italian Facility for J&J COVID-19 Vaccine 

The companies will use capacity at IDT previously reserved for Takeda’s dengue vaccine candidate, TAK-003, to manufacture Janssen Pharmaceutical’s single-shot COVID-19 vaccine. 

Takeda and IDT Biologika to Manufacture J&J’s COVID-19 Vaccine

Lonza will provide a manufacturing suite at its facility in Houston, TX, for the clinical and commercial production of AdCOVID, Altimmune’s single-dose intranasal vaccine candidate.

Lonza Expands Collaboration with Altimmune for its COVID-19 Vaccine Candidate

WuXi will produce SARS-CoV-2 s-proteins for BioVaxys’ COVID-19 vaccine candidate, BVX-0320, and for its Covid-T immunodiagnostic program.

BioVaxys and WuXi to Collaborate on SARS-CoV-2 S-Protein Production

Currently, supporters of the plan include the governments of Germany, Norway, and Ethiopia; Wellcome and the Bill and Melinda Gates Foundation; the World Economic Forum; and WHO, Gavi, and UNICEF.

CEPI Plans to Reduce Risk of Future Pandemics and Epidemics with Global Leaders’ Support and a $3.5 Billion Plan

Rokote Laboratories Finland, an academic spin-out located in Finland, is working to develop a nasal spray vaccine against COVID-19 based on research from the University of Helsinki and the University of Eastern Finland.

Vaccines